1. Home
  2. INBX

as of 02-13-2026 3:36pm EST

$76.49
$5.63
-6.85%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Founded: 2010 Country:
United States
United States
Employees: N/A City: LA JOLLA
Market Cap: 1.1B IPO Year: 2020
Target Price: N/A AVG Volume (30 days): 201.6K
Analyst Decision: Hold Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -10.03 EPS Growth: N/A
52 Week Low/High: $10.80 - $94.56 Next Earning Date: 03-16-2026
Revenue: $1,400,000 Revenue Growth: -19.26%
Revenue Growth (this year): 563% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: -143439000.0 FCF Growth: N/A

AI-Powered INBX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 72.26%
72.26%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: